BRIDGEWAY CAPITAL MANAGEMENT, LLC - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 56 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2019. The put-call ratio across all filers is 0.61 and the average weighting 0.0%.

Quarter-by-quarter ownership
BRIDGEWAY CAPITAL MANAGEMENT, LLC ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q1 2020$83,000
-51.7%
50,200
-35.1%
0.00%0.0%
Q4 2019$172,000
-45.2%
77,300
-47.5%
0.00%
-50.0%
Q3 2019$314,000
-42.8%
147,300
-28.1%
0.00%
-42.9%
Q2 2019$549,000
-9.9%
204,900
+65.6%
0.01%
-12.5%
Q1 2019$609,000123,7000.01%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q3 2019
NameSharesValueWeighting ↓
Kynam Capital Management, LP 1,605,390$71,552,23210.98%
Octagon Capital Advisors LP 761,398$33,935,5095.28%
TSP Capital Management Group, LLC 269,895$12,029,2254.50%
Redmile Group, LLC 1,977,451$88,134,9913.60%
COMMODORE CAPITAL LP 495,823$22,0993.33%
Tri Locum Partners LP 176,109$7,849,0003.18%
ACUTA CAPITAL PARTNERS, LLC 115,000$5,125,5503.15%
Ikarian Capital, LLC 267,476$11,921,4062.88%
RTW INVESTMENTS, LP 3,084,215$137,463,4632.81%
Eversept Partners, LP 558,774$24,904,5572.18%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders